Lymphoplasmacytic Lymphoma (LGL)/Waldenstrom Macroglobulinemia (WM) is a type of non-Hodgkin lymphoma (NHL). The cancer cells make large amounts of an abnormal protein (called a macroglobulin). The macroglobulin appears as an IgM monoclonal gammopathy in the blood. WM is a rare disorder with only about 1400 new cases diagnosed in the US every year. Patients with WM may develop anemia, lymphadenopathy, hepatosplenomegaly, hyperviscosity, peripheral neuropathy, fatigue, weakness, weight loss, or abnormal bleeding from the nose or gums. The physicians at CBCI specialize in the care of patients with WM and will discuss the many treatment options available for patients with WM.
To learn more about the disease, please watch the video below featuring Dr. Jeffrey Matous and Megan Andersen, APP.
Imbruvica has been approved by the FDA for treatment of adults with WM in combination use with Rituximab. NEJM